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NEW RESEARCH
Mental Health Problems and Onset of Tobacco Use
Among 12- to 24-Year-Olds in the PATH Study
Victoria R. Green, MHS, Kevin P. Conway, PhD, Marushka L. Silveira, BDS, MPH, PhD,
Karin A. Kasza, MA, Amy Cohn, PhD, K. Michael Cummings, PhD, MPH, Cassandra A. Stanton, PhD,
Priscilla Callahan-Lyon, MD, Wendy Slavit, MPH, CHES, James D. Sargent, MD, Nahla Hilmi, MPH,
Raymond S. Niaura, PhD, Chad J. Reissig, PhD, Elizabeth Lambert, MA, Izabella Zandberg, PhD,
Mary F. Brunette, MD, Susanne E. Tanski, MD, Nicolette Borek, PhD,
Andrew J. Hyland, PhD, Wilson M. Compton, MD, MPE
Objective: To examine whether mental health problems predict incident use of 12 different tobacco products in a nationally representative sample of
youth and young adults.
Method: This study analyzed Wave (W) 1 and W2 data from 10,533 12- to 24-year-old W1 never tobacco users in the Population Assessment of
Tobacco and Health (PATH) Study. Self-reported lifetime internalizing and externalizing symptoms were assessed at W1. Past 12-month use of
cigarettes, electronic nicotine delivery systems (ENDS), traditional cigars, cigarillos, filtered cigars, pipe, hookah, snus pouches, other smokeless tobacco,
bidis and kreteks (youth only), and dissolvable tobacco was assessed at W2.
Results: In multivariable regression analyses, high-severity W1 internalizing (adjusted odds ratio [AOR] ¼ 1.5, 95% CI ¼ 1.31.8) and externalizing
(AOR ¼ 1.3, 95% CI ¼ 1.11.5) problems predicted W2 onset of any tobacco use compared to no/low/moderate severity. High-severity W1
internalizing problems predicted W2 use onset across most tobacco products. High-severity W1 externalizing problems predicted onset of any tobacco
(AOR ¼ 1.6, 95% CI¼ 1.31.8), cigarettes (AOR¼ 1.4, 95% CI ¼ 1.02.0), ENDS (AOR¼ 1.8, 95% CI ¼ 1.52.1), and cigarillos (AOR ¼ 1.5,
95% CI ¼ 1.02.1) among youth only.
Conclusion: Internalizing and externalizing problems predicted onset of any tobacco use. However, findings differed for internalizing and exter-
nalizing problems across tobacco products, and by age, gender, and race/ethnicity. In addition to screening for tobacco product use, health care providers
should screen for a range of mental health problems as a predictor of tobacco use. Interventions addressing mental health problems may prevent youth
from initiating tobacco use.
Key words: young adult, tobacco, mental health, epidemiologic studies
J Am Acad Child Adolesc Psychiatry 2018;57(12):944–954.
lthough decreases in the overall prevalence of
cigarette use among youth and young adults in
the US have been observed over the past decade,
cigarette use among those with mental illness has remained
static since 2005.1-3 Furthermore, it has been reported that
individuals with serious mental illnesses have a life expec-
tancy 25 years shorter when compared to that of the general
population,4 with a bulk of the disparity attributed to
tobacco-related illnesses.5 The literature thus far has been
limited to examination of associations between mental
illness and cigarette use,5 despite increases in use of non-
cigarette products, such as e-cigarettes, hookah, and cigars
(eg, cigarillos), especially among US youth and
young adults.6 Therefore, it is critical to examine whether
mental illness predicts the onset of tobacco use across
products during adolescence and young adulthood, when
the risk of the onset of mental illness and substance use is
greatest.7,8
Few longitudinal studies have examined how internal-
izing problems (depression, anxiety) and externalizing
problems (conduct disorder, attention-deficit/hyperactivity
disorder [ADHD], oppositional defiant disorder) predict
tobacco use across products among youth and young adults.
Those studies that have examined the onset of tobacco use
among individuals with mental health problems are gener-
ally limited to cigarette use among youth.8-13 Although
studies of internalizing problems have shown that depres-
sion predicts the onset of cigarette use among youth,8-10
others have found mixed results for anxiety.11,12 Two
studies found that ADHD predicts the onset of cigarette use
A
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among youth,8,13 and one study among youth and young
adults found that ADHD plus co-existing conduct disorder or
oppositional defiant disorder predicted overall tobacco use in
the past year.14 In addition, higher depressive symptoms
among college students predicted e-cigarette use in the past 30
days.15 However, to our knowledge, no prospective study has
explored whether mental health problems predict the onset of
specific tobacco product use beyond cigarettes and e-cigarettes
among youth and young adults. As any use of a tobacco
product in this vulnerable age group has been shown to
predict future nicotine dependence,16 examining whether
mental health problems predict onset of tobacco use across
products is important for future tobacco prevention efforts.
Using data from Waves 1 and 2 of the Population
Assessment of Tobacco and Health (PATH) Study, the
present study investigated whether internalizing and exter-
nalizing problems at Wave 1 predicted the onset of use for
multiple types of tobacco products (ie, 12 products for youth;
10 products for young adults) at Wave 2 in a nationally
representative sample of youth and young adult never to-
bacco users. Based on the negative reinforcement model of
drug addiction,17 we hypothesized that those individuals
with higher severity of internalizing and externalizing prob-
lems would be more likely to begin using tobacco, regardless
of product type. Furthermore, because early onset of psy-
chopathology may be a marker for future tobacco use be-
haviors,18 we also examined whether the association between
mental health problems and tobacco use varied by age group.
METHOD
Study Design and Participants
The PATH Study is a national longitudinal cohort study of
45,971 adults and youth 12 years and older. The PATH
Study recruitment used a stratified address-based, area-
probability sampling design at Wave 1 that oversampled
adult tobacco users, young adults (1824 years), and Af-
rican American adults. Details on sampling, weighting,
survey interview procedures, questionnaires, and informa-
tion on accessing the data are available at http://doi.org/
10.3886/Series606. An in-person screener was used at
Wave 1 to select participants 12 years and over from
households. The study uses audio computer-assisted self-
Interviews (ACASI) available in English and Spanish to
collect self-report information on tobacco use patterns and
associated health behaviors. All participants 18 years of age
and older provided informed consent. Youth participants 12
to 17 years of age provided assent, whereas their parent/legal
guardian provided consent. The study was conducted by
Westat and approved by the Westat institutional review
board. Further details regarding the PATH Study design
and methods are published elsewhere.19
Population and replicate weights were created that
adjusted for the complex study design characteristics (eg,
oversampling at Wave 1) and nonresponse at Waves 1 and
2. Combined with the use of a probability sample, the
weights allow analyses of the PATH Study data to compute
estimates that are representative of the noninstitutionalized,
civilian US population aged 12 years and older. At Wave 1,
the weighted response rate for the household screener was
54.0%. Among households that were screened, the overall
weighted response rate at Wave 1 was 74.0% for the Adult
Interview and 78.4% for the Youth Interview. At Wave 2,
the overall weighted response rate was 83.2% for the Adult
Interview and 87.3% for the Youth Interview.
This article reports data from youth (aged 1217 years)
and young adults (1824 years) recruited at Wave 1
(September 2013 to December 2014) and followed up
approximately 1 year later (average period of follow-up, 52
weeks) at Wave 2 (October 2014 to October 2015) of the
PATH Study. The time between the interviews varied as a
function of respondents’ schedules, time needed to contact
respondents, and grouping of multiple respondents within a
household. As shown in Figure 1, the present analyses were
restricted to 10,533 Wave 1 youth (n ¼ 9,067) and young
adult (n ¼ 1,466) never tobacco users with data on tobacco
use, internalizing and externalizing problems, and covariates
for the specific associations examined.
Measures
Mental Health Problems. Mental health problems were
assessed via the Global Appraisal of Individual NeedsShort
Screener (GAIN-SS), modified for the PATH Study.20,21
The GAIN-SS is a 3- to 5-minute screener that identifies in-
dividuals at risk for mental health or substance use disorders
using a continuous measure of severity, based on the number of
items endorsed. Items for the GAIN-SS were derived from the
full GAIN instrument, a validated, standardized bio-
psychosocial assessment for individuals entering treatment for
substance use or mental health disorders22 and recommended
for use in epidemiological samples by the PhenXToolkit.23 The
PATH Study included four internalizing items, five external-
izing items, five substance use problem items, and two hyper-
activity items.22 Given this study’s focus on internalizing and
externalizing problems, the substance use problem subscale was
excluded from the analyses. In addition, as the externalizing and
hyperactivity items were found to be collinear, these seven items
were collapsed into one externalizing subscale.
The internalizing (youth Cronbach’s a ¼ 0.81; adult
Cronbach’s a ¼ 0.84) and externalizing (youth Cronbach’s
a ¼ 0.77; adult Cronbach’s a ¼ 0.79) subscales were found
to be internally consistent in the PATH Study.20,21 The
internalizing (r¼ 0.31, p< .001) and externalizing problems
Journal of the American Academy of Child & Adolescent Psychiatry www.jaacap.org 945
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(r ¼ 0.42, p < .001) subscales were also correlated with the
sum of three PROMIS (Patient-Reported Outcomes Mea-
surement Information System) items on self-rated physical
health, mental health, and overall health assessed among
adults only in the PATH Study. PROMIS measures have
been validated among the general US population24-26 and are
recommended for use by the PhenX Toolkit23 for scoring of
generic health-related quality of life.27
The number of responses endorsed for lifetime mental
health problems were summed for each subscale, and complete
data for subscale components were required (range, 04 for
internalizing problems and 07 for externalizing problems).
Based on the number of symptoms endorsed for each of the 2
subscales, respectively, participants were categorized into no/
low/moderate (03 symptoms) or high (4 symptoms for
internalizing problems or 4 symptoms for externalizing
FIGURE 1 Flow Chart for Participants Selected Into the Analytic Sample
Note: aWave 1 participants were lost to follow-up at Wave 2 for various standard reasons such as refusal, death, and other factors.
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problems) severity levels. These cutpoints were determined
based on previous analyses,20,21 with the goal of examining
those participants deemed to be at highest risk for a mental
health problem (ie, high-severity). Although the GAIN-SS is
not a diagnostic tool, no/low severity indicates a low likelihood
of diagnosis with need for services, moderate-severity indicates
a potential diagnosis with need for services, and high-severity
indicates a high likelihood of a diagnosis with need for
services.28
Tobacco Use. Participants were asked about ever use of
each tobacco product within the past 12 months at Wave 2,
including cigarettes, electronic nicotine delivery systems
(ENDS), traditional cigars, cigarillos, filtered cigars, pipe,
hookah, smokeless tobacco (ie, loose snus, moist snuff, dip,
spit, or chewing tobacco), snus pouches, bidis, kreteks, and
dissolvable tobacco. Only youth were asked about use of
bidis and kreteks, thus resulting in 12 tobacco products
assessed for youth and 10 tobacco products assessed for
young adults. A brief description and pictures of each
product (except cigarettes) were shown to participants when
asked about the products. Those who reported never using
any of the above listed 12 tobacco products for youth and
never using any of the above listed 10 tobacco products for
young adults at Wave 1 were defined as never tobacco users.
Wave 1 never users who reported ever use of a tobacco
product in the past 12 months at Wave 2 were classified as
“new users.” Due to assessment of e-cigarettes in Wave 1
and ENDS in Wave 2, new ENDS users were defined as
Wave 1 never e-cigarette users who reported ever use of
ENDS in the past 12 months at Wave 2. In Wave 2,
summary variables were created for use of the following
tobacco products: any tobacco (ie, any of the 12 [youth]/10
[young adults] tobacco products), any cigar (ie, traditional
cigars, cigarillos, or filtered cigars), and any smokeless form
of tobacco (ie, smokeless tobacco excluding snus pouches,
snus pouches, or dissolvable tobacco). Complete data were
required when defining nonuse for the summary variables.
Among Wave 2 new tobacco users, “new poly-users” of
tobacco product were defined as ever using 2 or more of the
following 10 tobacco products: cigarettes, ENDS, traditional
cigars, cigarillos, filtered cigars, pipe, hookah, snus pouches,
smokeless tobacco excluding snus pouches, and dissolvable
tobacco at Wave 2. “New exclusive users” of any tobacco
product were defined as ever using only one of these 10
tobacco products at Wave 2. Complete data were required to
categorize participants as new exclusive users but were not
required to categorize participants as new poly-users.
Covariates. Ever use of alcohol or any drug was assessed via
participants’ responses to questions on ever use of each of the
following at Wave 1: alcohol, marijuana (including blunts),
misuse of prescription drugs (ie, Ritalin or Adderall; painkillers,
sedatives, or tranquilizers), cocaine or crack, stimulants (ie,
methamphetamine or speed), heroin, inhalants, solvents, and
hallucinogens. Alcohol and drug use items in the PATH Study
were adapted from the National Epidemiologic Survey on
Alcohol and Related Conditions29 and the National Health
and Nutrition Examination Survey.30 Information was also
collected on socio-demographics, including age (1217 years,
1824 years), gender (male, female), race (white, black, Asian,
other including multi-racial), and ethnicity (Hispanic, not
Hispanic).
Statistical Analyses
Distributions of new use for each tobacco product at Wave 2,
according to severity of internalizing problems and external-
izing problems, respectively, at Wave 1 were examined.
Multivariable logistic regression analyses were used to evaluate
the associations between high-severity lifetime internalizing
and externalizing problems, respectively, and new tobacco use,
adjusting for socio-demographics, and ever any alcohol or drug
use at Wave 1. To address the high comorbidity of these
problems among youth and young adults,31 lifetime internal-
izing problems and externalizing problems were included in
the samemodel for each tobacco product. In addition, analyses
were repeated using 3-category variables: no/low (01 symp-
tom), moderate (23 symptoms), and high (4 symptoms for
internalizing problems or 4 symptoms for externalizing
problems) severity levels,28 as well as a 4-category variable (no/
low/moderate-severity internalizing/externalizing (referent),
high-severity internalizing only, high-severity externalizing
only, and high-severity internalizing/externalizing), and
continuous scores.
Age group (ie, youth/young adult) by lifetime inter-
nalizing problem interactions were tested (adjusted for
socio-demographics, ever any alcohol or drug use, and
lifetime externalizing problems), and age group by life-
time externalizing problem interactions were tested
(adjusted for socio-demographics, ever any alcohol or
drug use, and lifetime internalizing problems). Post hoc
exploratory analyses were conducted to examine whether
gender and race/ethnicity moderated the associations
between internalizing and externalizing problems and
new tobacco use.
Estimates were weighted to represent the US youth and
young adult populations; variances and CIs were estimated
using the balanced repeated replication (BRR) method32
with the Fay adjustment set to 0.3 to increase estimate
stability.33 Adjusted odds ratios (AORs) and 95% CIs were
calculated for all regression analyses. Two-sided p values
of <.05 were considered statistically significant. When
statistically significant interactions were identified for any
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specific contrast, stratified analyses were evaluated. Esti-
mates based on <50 observations in the denominator or
with a relative standard error >0.30 were suppressed.34
Based on these criteria, individual estimates for pipe,
bidis, kreteks, and dissolvable were suppressed in the tables
and figure. All analyses were conducted using Stata software,
version 14.35
RESULTS
Demographic characteristics of the sample have been re-
ported elsewhere.6,20,21 AtWave 1, 29% of youth and young
adults had high-severity internalizing problems in their life-
time, whereas 39% had lifetime high-severity externalizing
problems. At Wave 2, about 13% of youth and young adult
never tobacco users at Wave 1 started using any tobacco
products. The most commonly used product was ENDS
(10%), followed by hookah use (5%), and cigarettes (4%)
(Table 1 and Table 2).
Wave 2 New Tobacco Product Use by Lifetime Severity
of Internalizing and Externalizing Problems at Wave 1
Among Youth and Young Adult Never Tobacco Users
Table 1 presents the unadjusted distributions of new to-
bacco product use at Wave 2 by lifetime severity of inter-
nalizing problems at Wave 1. In models adjusting for socio-
demographics, alcohol or drug use, and externalizing
problems, youth and young adults with high-severity
internalizing problems were 1.5 times more likely to
begin using any tobacco product (95% CI ¼ 1.31.8)
compared to those with no/low/moderate severity inter-
nalizing problems. Associations were significant across all
tobacco products, except any smokeless tobacco and
TABLE 1 New Tobacco Product Use at Wave (W) 2 by Lifetime Severity of Internalizing Problems at W1 Among 9,067 Youth
(Aged 12–17 Years) and 1,466 Young Adult (Aged 18–24 Years) Never Tobacco Users in the Population Assessment of Tobacco
and Health (PATH) Study
New Tobacco Use
Between W1 and W2
(Never-P12 Month Use)
New Tobacco Use
Among W1
Never Usersa
W1 Internalizing Problems
No/Low/Moderate
Severity
(Referent) 71.4%b High Severity 28.6%b
Unweighted
n
Weighted %
(SE)c
Unweighted
n
Weighted %
(SE)c
Unweighted
n
Weighted %
(SE)c AORd 95% CId
Any tobacco 1321 13.4 (.5) 764 11.4 (.5) 557 18.3 (1.0) 1.5 1.3e1.8
Cigarettes 393 4.1 (0.2) 206 3.2 (0.2) 187 6.4 (0.6) 2.2 1.7e3.0
ENDS 1147 10.4 (0.4) 653 8.7 (0.4) 494 14.6 (0.8) 1.4e 1.2e1.7
Any cigar 300 3.4 (0.3) 165 2.5 (0.3) 135 5.5 (0.6) 2.2 1.5e3.0
Traditional cigars 135 1.8 (0.2) 73 1.4 (0.2) 62 2.7 (0.4) 2.1 1.3e3.2
Cigarillos 217 2.2 (0.2) 126 1.7 (0.2) 91 3.5 (0.4) 2.0 1.3e3.2
Filtered cigars 56 0.5 (0.1) 25 0.3 (0.1) 31 1.0 (0.2) 2.6 1.5e4.7
Pipe 32 0.3 (0.1) 22 0.3 (0.1) ⱡf ⱡf ⱡf ⱡf
Hookah 405 4.7 (0.3) 229 4.1 (0.4) 176 6.4 (0.5) 1.5 1.1e2.1
Any smokeless tobaccog 120 1.1 (0.1) 83 1.1 (0.1) 37 1.1 (0.2) 1.2 0.8e1.8
Smokeless tobacco
(excluding snus
pouches)
93 0.9 (0.1) 66 0.9 (0.1) 27 0.8 (0.1) 1.1 0.7e1.6
Snus pouches 40 0.4 (0.1) 25 0.3 (0.1) 15 0.5 (0.1) #h
Note: Statistically significant associations at p < .05 indicated in boldface type. Estimates weighted using W2 longitudinal weights. ⱡ ¼ suppressed
estimate; AOR ¼ adjusted odds ratio; ENDS ¼ electronic nicotine delivery systems; P12 ¼ past 12; SE ¼ standard error.
aRestricted to those with W1 internalizing problem data.
bPercentages (%)s represent the prevalence of W1 lifetime internalizing problems.
cPercentages (%)s and SEs represent the prevalence of new tobacco use between W1 and W2 by W1 lifetime internalizing problems.
dAORs and 95% CIs indicate the odds of new tobacco use between W1 and W2 as a function of lifetime internalizing problems; adjusted for age group
(12–17 vs. 18–24), gender, race, ethnicity, ever any alcohol or drug use at W1, and other externalizing problems at W1.
eIndicates significant race/ethnicity interaction at p < .05.
fEstimate has been suppressed because it is statistically unreliable. It is based on a (denominator) sample size of < 50, or the coefficient of variation of
the estimate (or its complement) is > 30%. Estimates for bidis, kreteks, and dissolvable tobacco have been suppressed based on these criteria.
gIncludes snus pouches, smokeless tobacco excluding snus pouches, and dissolvables.
hModel did not run.
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smokeless tobacco excluding snus pouches. The strongest
associations were observed for new filtered cigar use
(AOR ¼ 2.6, 95% CI ¼ 1.54.7) and new cigarette use
(AOR ¼ 2.2, 95% CI ¼ 1.73.0). The results for pipe and
kreteks were statistically unreliable, and models did not
converge for snus pouches, bidis, and dissolvables.
Table 2 presents the unadjusted distributions of new
tobacco product use at Wave 2 by lifetime severity of
externalizing problems at Wave 1. In adjusted models,
youth and young adults with high-severity externalizing
problems were more likely to begin using any tobacco
product (AOR ¼ 1.3, 95% CI ¼ 1.11.5). Regarding
specific tobacco products, high-severity externalizing prob-
lems at Wave 1 predicted only new ENDS use (AOR¼ 1.4,
95% CI ¼ 1.11.7) at Wave 2, whereas other products did
not reach statistical significance when examined
individually.
Examination of the GAIN-SS as a three-category vari-
able (no/low severity [referent], moderate severity, and high
severity) for internalizing and externalizing problems
(Tables S1 and S2, available online), as well as a four-
category variable (no/low/moderate severity internalizing/
externalizing [referent], high-severity internalizing only,
high-severity externalizing only, and high-severity inter-
nalizing/externalizing) (Table S3, available online) yielded
results similar to those in Tables 1 and 2. Internalizing and
externalizing problems were also analyzed as continuous
scores with similar results for new any tobacco use and new
tobacco productspecific use to Tables 1 and 2 (results not
shown). Each one symptom increase on the internalizing
TABLE 2 New Tobacco Product Use at Wave (W) 2 by Lifetime Severity of Externalizing Problems at W1 Among 9,067 Youth
(Aged 12–17 Years) and 1,466 Young Adult (Aged 18–24 Years) Never Tobacco Users in the Population Assessment of Tobacco
and Health (PATH) Study
New Tobacco Use
Between W1 and W2
(Never-P12 Month Use)
New Tobacco Use
Among W1
Never Usersa
W1 Externalizing Problems
No/Low/Moderate
Severity
(Referent) 60.8%b High Severity 39.2%b
Unweighted
n
Weighted %
(SE)c
Unweighted
n
Weighted %
(SE)c
Unweighted
n
Weighted %
(SE)c AORd 95% CId
Any tobacco 1297 13.3 (0.5) 580 11.0 (0.5) 717 16.9 (0.9) 1.3e,f,g 1.1e1.5
Cigarettes 389 4.1 (0.2) 174 3.6 (0.3) 215 4.8 (0.4) 0.9e 0.7e1.2
ENDS 1130 10.4 (0.4) 477 8.0 (0.5) 653 14.0 (0.8) 1.4e,f,g 1.1e1.7
Any cigar 298 3.4 (0.3) 131 2.8 (0.3) 167 4.3 (0.4) 1.0 0.7e1.4
Traditional cigars 132 1.8 (0.2) 64 1.6 (0.2) 68 2.0 (0.3) 0.9 0.5e1.3
Cigarillos 218 2.3 (0.2) 98 2.0 (0.2) 120 2.8 (0.3) 0.9e 0.6e1.4
Filtered cigars 55 0.5 (0.1) 23 0.4 (0.1) 32 0.7 (0.1) 0.9 0.5e1.7
Pipe 31 0.3 (0.1) ⱡh ⱡh 17 0.3 (0.1) ⱡh ⱡh
Hookah 395 4.7 (0.3) 187 4.2 (0.3) 208 5.5 (0.5) 1.1f 0.8e1.5
Any smokeless tobaccoi 120 1.2 (0.1) 63 1.1 (0.2) 57 1.2 (0.2) 0.9g 0.5e1.4
Smokeless tobacco
(excluding snus
pouches)
92 0.9 (0.1) 53 1.0 (0.2) 39 0.8 (0.1) 0.7g 0.4e1.1
Snus pouches 39 0.4 (0.1) 17 0.3 (0.1) 22 0.5 (0.1) #j
Note: Statistically significant associations at p < .05 indicated in boldface type. Estimates weighted using W2 longitudinal weights. ⱡ ¼ suppressed
estimate; AOR ¼ adjusted odds ratio; ENDS ¼ electronic nicotine delivery systems; P12 ¼ past 12; SE ¼ standard error.
aRestricted to those with W1 externalizing problem data.
bPercentages (%)s represent the prevalence of W1 lifetime externalizing problems.
cPercentages (%)s and SEs represent the prevalence of new tobacco use between W1 and W2 by W1 lifetime externalizing problems.
dAORs and 95% CIs indicate the odds of new tobacco use between W1 and W2 as a function of lifetime externalizing problems; adjusted for age
group (12–17 vs. 18–24), gender, race, ethnicity, ever any alcohol or drug use at W1, and internalizing problems at W1.
eIndicates significant age interaction at p < .05.
fIndicates significant gender interaction at p < .05.
gIndicates significant race/ethnicity interaction at p < .05.
hEstimate has been suppressed because it is statistically unreliable. It is based on a (denominator) sample size of < 50, or the coefficient of variation of
the estimate (or its complement) is >30%. Estimates for bidis, kreteks, and dissolvable tobacco have been suppressed based on these criteria.
iIncludes snus pouches, smokeless tobacco excluding snus pouches, and dissolvables.
jModel did not run.
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(AOR ¼ 1.1, 95% CI ¼ 1.01.1) and externalizing
(AOR ¼ 1.1, 95% CI ¼ 1.01.1) scale, respectively, was
significantly associated with new any tobacco product use.
Wave 2 New Exclusive and PolyTobacco Product Use
by Lifetime Severity of Internalizing and Externalizing
Problems at Wave 1 Among Youth and Young Adult
Never Tobacco Users
Table 3 presents the unadjusted distributions of new
exclusive and polytobacco product use at Wave 2 by
lifetime severity of internalizing and externalizing problems,
respectively, at Wave 1. In multinomial models adjusting
for socio-demographics, alcohol or drug use, and external-
izing problems, youth and young adults with high-severity
internalizing problems were about 1.3 times more likely
(95% CI ¼ 1.01.5) to report new exclusive use of any
tobacco product and about 1.8 times more likely (95%
CI ¼ 1.42.3) to report new poly-use of any tobacco
product. Similarly, youth and young adults with high-
severity externalizing problems were more likely to report
new exclusive use of any tobacco product (AOR ¼ 1.6,
95% CI ¼ 1.32.0); however, findings were not significant
for new poly-tobacco use.
Age, Gender, and Race/Ethnicity Interactions Between
Lifetime Severity of Internalizing and Externalizing
Problems at Wave 1 and New Tobacco Product Use at
Wave 2
There were no significant age or gender interactions across
products for internalizing problems (Table 1). However,
there was a significant race/ethnicity interaction for new
ENDS use (p ¼ .034), such that white youth and young
adults with high-severity internalizing problems were
significantly more likely to report new ENDS use
(AOR ¼ 1.6; 95% CI ¼ 1.22.1); this association was not
significant among black youth and young adults.
Age significantly moderated the association between
externalizing problems for any tobacco product (p ¼ .002),
cigarettes (p ¼ .002), ENDS (p ¼ .001), and cigarillos (p ¼
.046); stratified results are presented in Figure 2. New use of
any tobacco, cigarettes, ENDS, and cigarillos was more likely
among youth with high-severity externalizing problems than
youth with no/low/moderate-severity externalizing problems.
In adjusted models, the strongest association across products
was observed for onset of ENDS among youth with high-
severity externalizing problems (AOR ¼ 1.8, 95% CI ¼
1.52.1) compared to youth with no/low/moderate-severity
externalizing problems, followed by cigarillos (AOR ¼ 1.5,
95% CI ¼ 1.02.1) and cigarettes (AOR ¼ 1.4, 95%
CI ¼ 1.02.0).
In addition, gender significantly moderated the association
between high-severity externalizing problems at Wave 1 and
new tobacco product use at Wave 2. Specifically, female youth
and young adults with high-severity externalizing problems
were more likely to report new use of any tobacco product
(AOR ¼ 1.4, 95% CI ¼ 1.11.9) and ENDS (AOR ¼ 1.5,
95% CI ¼ 1.22.0), respectively, in comparison to male
youth and young adults with high-severity externalizing
problems. Associations with new hookah use were also
stronger for female youth and young adults with high-severity
externalizing problems in comparison to male youth and
young adults with high-severity externalizing problems, but
stratified results were not significant.
Significant race/ethnicity interactions were also observed
for new any tobacco use, ENDS use, any smokeless tobacco
use, and smokeless tobacco use excluding snus pouches. Spe-
cifically, white youth and young adults with high-severity
externalizing problems were significantly more likely to
report new any tobacco (AOR ¼ 1.4; 95% CI ¼ 1.11.7)
and ENDS use (AOR ¼ 1.4; 95% CI ¼ 1.11.8); however,
no significant associations were observed for Hispanic and
black youth and young adults, respectively. In contrast, youth
and young adults with high-severity externalizing problems
belonging to other racial/ethnic groups were significantly less
likely to report new any smokeless tobacco use (AOR ¼ 0.1;
95% CI ¼ 0.00.7) and new smokeless tobacco use
excluding snus pouches (AOR ¼ 0.1; 95% CI ¼ 0.00.7);
however, no significant associations were observed for white
and black youth and young adults.
DISCUSSION
In this nationally representative sample of youth and young
adult never tobacco users, internalizing and externalizing
problems each independently predicted onset of any to-
bacco use. Associations were robust to important con-
founders,16,20,21 including alcohol or any drug use and
comorbid mental health problems. Across tobacco products,
however, findings differed for internalizing and externalizing
problems, as well as by age, gender, and race/ethnicity.
Internalizing problems predicted the onset of nearly all to-
bacco product use assessed among youth and young adults,
thereby extendingfindings of prior research focusedon cigarettes
among youth.8-10 Although our findings linking internalizing
problems to tobacco use are consistent across products, prior
studies have generated mixed results for internalizing problems
and tobacco use associations.8-12 These differences could be due
to definitional approaches used, including our assessment of
mental health symptoms versus diagnoses,8,10,12 and collapsing
depression and anxiety rather than separating as has beendone in
other studies. In addition, differences in samples (eg, clinical
versus population-based) may be a factor in accounting for
divergent findings. Nonetheless, our results suggest that inter-
nalizing problems are a strong signal for the onset of tobacco use
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across a wide range of products. Furthermore, findings of a
doseresponse relationship between internalizing problems and
onset of exclusive and polytobacco use, respectively, suggest
that youth and young adults with internalizing problems were
not only more likely to begin using tobacco products compared
to those without internalizing problems, but were also more
likely to begin using multiple tobacco products.
Externalizing problems similarly predicted the onset of any
tobacco use among youth and young adults. However, across
products, the only significant association was observed for the
onset of ENDS use, likely driving the “any tobacco use” as-
sociation. ENDS use also appeared to drive the significant as-
sociation between externalizing problems and new exclusive
use of any tobacco product, but not poly-tobacco use. One
plausible interpretation is that youth and young adults with
behavioral problems may be attracted to new products such as
ENDS, as these individuals may be intrigued by novel
stimuli and experiences. From an environmental exposure
perspective, individuals with behavioral issues may be
introduced to ENDS through peers or friends who use
ENDS, which are often consumed in social contexts.36
Future studies can examine whether youth and young
adults with externalizing problems are more likely to start
use of ENDS in comparison to other tobacco products.
In addition, age interactions were observed for external-
izing psychopathology in which youth with high-severity
problems were more likely to begin using cigarettes, ENDS,
and cigarillos than youth classified as no/low/moderate
severity. One study found that while externalizing psycho-
pathology robustly predicted early onset of cigarette use by age
14 years, internalizing was a weaker predictor, perhaps because
the internalizingsubstance pathway emerges later in
adolescence.37 Our findings that externalizing problems pre-
dicted the onset of cigarette, ENDS, and cigarillo use among
youth further implicates externalizing problems among youth
as risk factors for use of these tobacco products.
The results from this study should also be interpreted
within the context of the significant gender and race/
ethnicity interactions observed, although findings were not
consistent across mental health problems or tobacco prod-
ucts. The stronger associations for any tobacco, ENDS, and
hookah use among female compared to male youth and
young adults with externalizing problems support and
extend previous cross-sectional findings from the PATH
Study.20,21 In addition, white youth and young adults with
internalizing and externalizing problems, respectively, were
more likely to report new ENDS use in comparison to other
racial/ethnic groups with internalizing and externalizing
problems, respectively. Taken together, the age, gender, and
race/ethnicity interactions suggest that white female youth
with externalizing problems may be particularly drawn toT
A
B
LE
3
N
ew
E
xc
lu
si
ve
an
d
Po
ly
T
ob
ac
co
Pr
od
uc
t
U
se
at
W
av
e
(W
)2
b
y
Li
fe
ti
m
e
Se
ve
ri
ty
of
In
te
rn
al
iz
in
g
an
d
E
xt
er
na
liz
in
g
Pr
ob
le
m
s
at
W
1
A
m
on
g
9,
06
7
Y
ou
th
(1
2
17
ye
ar
s)
an
d
1,
46
6
Y
ou
ng
A
d
ul
t
(1
8
24
ye
ar
s)
N
ev
er
To
b
ac
co
U
se
rs
in
th
e
Po
p
ul
at
io
n
A
ss
es
sm
en
t
of
To
b
ac
co
an
d
H
ea
lt
h
(P
A
TH
)
St
ud
y
N
ew
To
b
ac
co
U
se
B
et
w
ee
n
W
1
an
d
2
(N
ev
er
-P
12
M
o
nt
h
U
se
)
W
1
In
te
rn
al
iz
in
g
P
ro
b
le
m
s
W
1
E
xt
er
na
liz
in
g
P
ro
b
le
m
s
N
o
/L
o
w
/M
o
d
er
at
e
Se
ve
ri
ty
(r
ef
er
en
t)
71
.4
%
a
H
ig
h
Se
ve
ri
ty
28
.6
%
a
N
o
/L
o
w
/M
o
d
er
at
e
Se
ve
ri
ty
(R
ef
er
en
t)
60
.8
%
a
H
ig
h
Se
ve
ri
ty
39
.2
%
a
U
nw
ei
g
ht
ed
n
W
ei
g
ht
ed
%
(S
E
)b
U
nw
ei
g
ht
ed
n
W
ei
g
ht
ed
%
(S
E
)b
A
O
R
c
95
%
C
Ic
U
nw
ei
g
ht
ed
n
W
ei
g
ht
ed
%
(S
E
)b
U
nw
ei
g
ht
ed
n
W
ei
g
ht
ed
%
(S
E
)b
A
O
R
c
95
%
C
Ic
Ex
cl
us
iv
e
U
se
43
0
6.
4
(0
.4
)
29
2
9.
5
(0
.7
)
1.
3
(1
.0
e
1.
5)
31
3
5.
6
(0
.4
)
39
6
9.
8
(0
.7
)
1.
6
(1
.3
e
2.
0)
Po
ly
-u
se
33
2
5.
1
(0
.3
4)
26
3
8.
8
(0
.7
)
1.
8
(1
.4
e
2.
3)
26
5
5.
4
(0
.4
)
32
1
7.
3
(0
.5
)
1.
0
(0
.8
e
1.
3)
N
ot
e:
Es
tim
at
es
w
ei
g
ht
ed
us
in
g
W
2
lo
ng
itu
d
in
al
w
ei
g
ht
s.
N
o
ne
w
to
b
ac
co
us
e
b
et
w
ee
n
W
1
an
d
2
is
th
e
re
fe
re
nt
g
ro
up
.A
O
R
¼
ad
ju
d
te
d
od
d
s
ra
tio
s;
P1
2
¼
p
as
t
12
;S
E
¼
st
an
da
rd
er
ro
r.
St
at
is
tic
al
ly
si
g
ni
fi
ca
nt
as
so
ci
at
io
ns
at
p
<
.0
5
in
d
ic
at
ed
in
b
ol
d
fa
ce
ty
p
e.
a P
er
ce
nt
ag
es
(%
)s
re
p
re
se
nt
th
e
p
re
va
le
nc
e
of
W
1
lif
et
im
e
m
en
ta
lh
ea
lth
p
ro
b
le
m
s.
b
Pe
rc
en
ta
g
es
(%
)s
an
d
SE
s
re
p
re
se
nt
th
e
p
re
va
le
nc
e
of
ne
w
to
b
ac
co
us
e
b
et
w
ee
n
W
1
an
d
W
2
b
y
W
1
lif
et
im
e
m
en
ta
lh
ea
lth
p
ro
b
le
m
s.
c A
O
Rs
an
d
95
%
C
Is
in
d
ic
at
e
th
e
od
d
s
of
ne
w
to
b
ac
co
us
e
b
et
w
ee
n
W
1
an
d
W
2
as
a
fu
nc
tio
n
of
lif
et
im
e
m
en
ta
lh
ea
lth
p
ro
b
le
m
s;
ad
ju
st
ed
fo
ra
g
e
g
ro
up
(1
2–
17
vs
.1
8–
24
ye
ar
s)
,g
en
d
er
,r
ac
e,
et
hn
ic
ity
,e
ve
r
an
y
al
co
ho
lo
r
d
ru
g
us
e
at
W
1,
an
d
ot
he
r
m
en
ta
lh
ea
lth
p
ro
bl
em
s
at
W
1
(ie
,i
nt
er
na
liz
in
g
p
ro
b
le
m
s
an
al
ys
es
ad
ju
st
ed
fo
r
ex
te
rn
al
iz
in
g
p
ro
b
le
m
s,
an
d
ex
te
rn
al
iz
in
g
p
ro
b
le
m
s
an
al
ys
es
ad
ju
st
ed
fo
r
in
te
rn
al
iz
in
g
p
ro
b
le
m
s)
.
Journal of the American Academy of Child & Adolescent Psychiatry www.jaacap.org 951
Volume 57 / Number 12 / December 2018
COMORBIDITY AMONG 12- TO 24-YEAR-OLDS
new use of ENDS, suggesting that targeted interventions for
this group may be most efficiacious for reducing mental
health problems38 and tobacco use.
Neither internalizing nor externalizing problems were
associated with any smokeless tobacco use, suggesting that
youth and young adults with mental health problems are not
disproportionately drawn to this class of tobacco products. The
few studies that have examined the profiles of smokeless tobacco
users have focused on demographic indicators. Although prior
studies found the most common smokeless tobacco users to be
white middle-aged or older males generally of lower socioeco-
nomic status,39,40 a recent study found that smokeless tobacco
use was most common among males, younger adults, non-
Hispanic whites, and individuals residing in nonurban
areas.41 Interestingly, we observed racial/ethnic differences in
the association between externalizing problems and smokeless
tobacco, suggesting a protective association for other racial/
ethnic groups. It is therefore important to consider interactions
between demographic and psychosocial factors that may be
unique to this class of products to better understand risk and
protective factors for smokeless tobacco use.
This study has several important strengths, as well as some
limitations. First, it is one of the first to assess the onset of
tobacco use among youth and young adults as a function of
internalizing and externalizing problems in a nationally
representative sample. Second, this study provides a compre-
hensive assessment of tobacco product use, which is rapidly
evolving as new products gain favor in the marketplace.
Although examination of specific tobacco products in this
study advances prior research, small cell sizes for some tobacco
products may have limited statistical power to detect associa-
tions. Third, the study included important covariates that
allow for adjustment of potential confounding, such as de-
mographics, alcohol or any drug use, and comorbid mental
health problems. All of these covariates were predictors of
onset of tobacco product use, with alcohol or any drug use
strongly predicting new tobacco use. Future studies can
examine how alcohol or drug use is associated with onset and
continued tobacco product use.
Some potential confounders that could have an impact
on the association between mental health problems and to-
bacco use were excluded, such as sensation seeking (assessed
among youth but not adults), peer influence (not assessed in
Waves 1 and 2), and socioeconomic status (not assessed
directly in Wave 1). However, including education as a co-
variate (ie, parent’s highest level of education for youth and
the highest level of education reported by young adults as
proxies for socioeconomic status) had no substantial effect on
FIGURE 2 New Tobacco Product Use at Wave 2 by Lifetime Severity of Externalizing Problems at Wave 1 Stratified by Age (ie,
9,067 youth versus 1,466 young adults) in the Population Assessment of Tobacco and Health (PATH) Study
Note: Estimates weighted using W2 longitudinal weights. Age (ie youth [1217 years] versus adult [1824 years]) by lifetime severity externalizing problems interactions
significant at p < .05. Age-stratified data shown for proportions of new tobacco product use at Wave 2 by lifetime severity externalizing problems. Adjusted odds ratios
(AORs) and 95% CIs from multivariable logistic regression models adjusting for gender, race/ethnicity, ever substance use, and lifetime internalizing problems at Wave 1.
Statistically significant associations at p < 0.05 indicated in boldface type. Please note color figures are available online.
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the observed estimates. It should also be noted that statistical
correction for multiple tests was not applied to the models, as
applying such a correction would require adjusting p values
for significance to a level that would be too conservative.
Therefore, it remains a possibility that multiple testing may
have resulted in obtaining significant results by chance alone.
The PATH Study included a noninstitutionalized popula-
tion, and thus our results may not be generalized to in-
dividuals in an institutional setting. Furthermore, as the
PATH Study did not collect information about prior insti-
tutionalization, we were unable to assess its effect on our
findings.
Fourth, although this study did not include diagnoses
for internalizing and externalizing disorders, the high
sensitivity and specificity between GAIN-SS items and
psychiatric diagnoses supports the use of this measure as a
strong indicator of significant mental health problems.22
Fifth, to the extent that externalizing problems are a pre-
dictor of early tobacco use,37,42 our exclusion of Wave 1
tobacco users may have contributed to the inconsistent as-
sociations that we found between externalizing and tobacco
use; that is, it is possible that individuals with externalizing
problems who had already initiated tobacco use were
excluded.20,21 When stratified by age, externalizing prob-
lems predicted the onset of cigarette, ENDS, and cigarillo
use among youth, further supporting this hypothesis.
Finally, although longitudinal associations were identified
between mental health and tobacco use, causality cannot be
determined by this epidemiologic study. Future assessments
of mental health and tobacco use with additional waves of
data collection in the PATH Study could help to inform our
understanding of the progression of tobacco use (ie, fre-
quency and intensity of tobacco use, dual use, ability to stop
using tobacco) among individuals with and without mental
health problems over time. Although this study examined
how mental health problems are associated with the onset of
tobacco use, future studies can examine the reverse direc-
tion, that is, how tobacco use may be associated with the
onset of mental health problems among youth and young
adults.5
In summary, this study demonstrates that mental health
problems predict the onset of tobacco use among youth and
young adults in a nationally representative sample, and across
a wide range of tobacco products beyond cigarettes. A nega-
tive reinforcement model of drug addiction would suggest
that tobacco use is initiated to ameliorate mental distress, but
we cannot rule out the possibility that these associations are
potentially driven by a common underlying factor of envi-
ronmental, familial, or genetic risk for bothmental illness and
tobacco use.5,20 Researchers can continue to investigate
internalizing and externalizing problems as potential etiologic
factors for the onset of tobacco use, including examination of
mediators and moderators of tobacco use made possible by
the PATH Study’s longitudinal data. In addition, reporting
on initiatives to expand mental health and substance use
screening in health care settings is often voluntary.43 Rec-
ommended measures also do not comprehensively screen
across tobacco products used by youth and young adults, or
focus on monitoring severe mental health and substance use
disorders that have already been diagnosed.44,45 Thus, the
need for early and specific tobacco product use screening, as
well as screening across the spectrum of mental health
problems, as tools to prevent tobacco product use onset is
apparent. Providing incentives to providers to link these two
screening mechanisms could increase the overall intergration
of these services in clinical practice.
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TABLE S1 New Tobacco Product Use at Wave (W) 2 by Lifetime Severity (No/Low, Moderate, and High) of Internalizing
Problems at Wave 1 Among 9,067 Youth (1217 Years) and 1,466 Young Adult (1824 years) Never Tobacco Users in the
Population Assessment of Tobacco and Health (PATH) Study
New Tobacco
Use Between
W1 and W2
(Never-P12
Month Use)
New Tobacco Use
Among W1
Never Usersa
Wave 1 Internalizing Problems
No/Low Severity
(Referent)
41.1%b Moderate Severity 30.2%b High Severity 28.6%b
Unweighted
n
Weighted
% (SE)
Unweighted
n
Weighted
% (SE)c
Unweighted
n
Weighted
% (SE)c AORd
95%
CId
Unweighted
n
Weighted
% (SE)c AORd
95%
CId
Any tobacco 1321 13.4 (.5) 370 10.2 (.6) 394 12.9 (.9) 1.1 (0.9, 1.4) 557 18.3 (1.0) 1.6 (1.2, 2.0)
Cigarettes 393 4.1 (.2) 110 3.3 (.3) 96 3.0 (.4) 1.0 (0.7, 1.5) 187 6.4 (.6) 2.2 (1.5, 3.3)
ENDS 1147 10.4 (.4) 308 7.5 (.5) 345 10.2 (.8) 1.1 (0.9, 1.4) 494 14.6 (.8) 1.4 (1.1, 1.8)
Any cigar 300 3.4 (.3) 86 2.4 (.3) 79 2.8 (.4) 1.1 (0.7, 1.7) 135 5.3 (.6) 2.1 (1.3, 3.5)
Traditional
cigars
135 1.8 (.2) 44 1.3 (.2) 29 1.3 (.2) 0.8 (0.4, 1.5) 62 2.7 (.4) 1.8 (0.9, 3.6)
Cigarillos 217 2.2 (.2) 63 1.5 (.2) 63 2.0 (.3) 1.4 (0.9, 2.2) 91 3.5 (.4) 2.5 (1.5, 4.3)
Filtered cigars 56 0.5 (.1) 14 0.3 (.1) ⱡe ⱡe 1.4 (0.5, 4.2) 31 1.0 (.2) 3.3 (1.4, 8.1)
Pipe 32 0.3 (.1) ⱡe ⱡe ⱡe ⱡe 1.0 (0.3, 3.2) ⱡe ⱡe 0.7 (0.2, 2.2)
Hookah 405 4.7 (.3) 106 3.5 (.4) 123 4.8 (.6) 1.3 (0.9, 1.9) 176 6.4 (.5) 1.8 (1.2, 2.7)
Any smokeless
tobaccof
120 1.1 (.1) 43 1.2 (.2) 40 1.1 (.2) 0.9 (0.5, 1.4) 37 1.1 (.2) 1.1 (0.6, 1.8)
Smokeless
tobacco
(excluding
snus
pouches)
93 0.9 (.1) 38 1.1 (.2) 28 0.7 (.1) 0.6 (0.4, 1.2) 27 0.8 (.1) 0.8 (0.5, 1.4)
Snus pouches 40 0.4 (.1) 13 0.4 (.l) ⱡe ⱡe #g 15 0.5 (.1) #g
Note: Statistically significant associations at p < .05 indicated in boldface type. Estimates weighted using W2 longitudinal weights. ⱡ ¼ suppressed
estimate; AOR ¼ adjusted odds ratio; ENDS ¼ electronic nicotine delivery systems; P12 ¼ past 12; SE ¼ standard error.
aRestricted to those with Wave 1 internalizing problem data.
bPercentages (%) represent the prevalence of Wave 1 lifetime internalizing problems.
cPercentages (%) and standard errors (SE) represent the prevalence of new tobacco use between W1 and W2 by W1 lifetime internalizing problems.
dAdjusted odds ratios (AOR) and 95% CI indicate the odds of new tobacco use between W1 and W2 as a function of lifetime internalizing problems;
adjusted for age group (12–17 vs 18–24 years), gender, race, ethnicity, ever any substance use at W1, and other externalizing problems at W1.
eEstimate has been suppressed because it is statistically unreliable. It is based on a (denominator) sample size of less than 50, or the coefficient of
variation of the estimate (or its complement) is larger than 30%.
fIncludes snus pouches, smokeless tobacco excluding snus pouches, and dissolvables.
gModel did not run. Estimates for bidis, kreteks, and dissolvable tobacco have been suppressed based on these criteria.
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TABLE S2 New Tobacco Product Use at Wave (W) 2 by Lifetime Severity (No/Low, Moderate, and High) of Externalizing
Problems at Wave 1 Among 9,067 Youth (1217 Years) and 1,466 Young Adult (1824 years) Never Tobacco Users in the
Population Assessment of Tobacco and Health (PATH) Study
New Tobacco
Use Between
W1 and W2
(Never-P12
Month Use)
New Tobacco Use
Among W1
Never Usersa
Wave 1 Externalizing Problems
No/Low Severity
(Referent)
32.1%b Moderate Severity 28.8%b High Severity 39.2%b
Unweighted
n
Weighted
% (SE)c
Unweighted
n
Weighted
% (SE)c
Unweighted
n
Weighted
% (SE)c AORd
95%
CId
Unweighted
n
Weighted
% (SE)c AORd
95%
CId
Any tobacco 1297 13.3 (.5) 245 9.6 (.7) 335 12.6 (.9) 1.1 (0.9, 1.4) 717 16.9 (.9) 1.3 (1.1, 1.7)
Cigarettes 389 4.1 (.2) 77 3.3 (.4) 97 4.1 (.5) 0.9 (0.7, 1.4) 215 4.8 (.4) 0.9 (0.6, 1.3)
ENDS 1130 10.4 (.4) 180 6.4 (.6) 297 9.7 (.7) 1.3 (1.0, 1.7) 653 14.0 (.8) 1.6 (1.2, 2.1)
Any cigar 298 3.4 (.3) 57 2.2 (.3) 74 3.5 (.5) 1.3 (0.8, 2.0) 167 4.3 (.4) 1.1 (0.7, 1.8)
Traditional
cigars
132 1.8 (.2) 28 1.3 (.3) 36 1.9 (.3) 1.1 (0.6, 2.2) 68 2.0 (.3) 1.0 (0.5, 2.0)
Cigarillos 218 2.3 (.2) 47 1.8 (.3) 51 2.1 (.4) 0.9 (0.6, 1.4) 120 2.8 (.3) 0.8 (0.5, 1.3)
Filtered cigars 55 0.5 (.l) ⱡg ⱡg ⱡg ⱡg 0.8 (0.2, 2.4) 32 0.7 (.1) 0.7 (0.3, 1.9)
Pipe 31 0.3 (.1) ⱡg ⱡg ⱡg ⱡg 1.6 (0.5, 5.2) 17 0.3 (.1) 1.1 (0.4, 3.5)
Hookah 395 4.7 (.3) 90 3.9 (.5) 97 4.5 (.5) 0.9 (0.6, 1.4) 208 5.5 (.5) 1.0 (0.7, 1.5)
Any smokeless
tobaccoe
120 1.2 (.1) 26 1.0 (.2) 37 1.2 (.3) 1.1 (0.7, 1.8) 57 1.2 (.2) 0.9 (0.6, 1.5)
Smokeless
tobacco
(excluding
snus
pouches)
92 0.9 (.1) 22 0.9 (.2) 31 1.0 (.2) 1.1 (0.6, 2.0) 39 0.8 (.1) 0.8 (0.5, 1.4)
Snus pouches 39 0.4 (.1) ⱡg ⱡg ⱡg ⱡg #f 22 0.5 (.1) #f
Note: Statistically significant associations at p < .05 indicated in boldface type. Estimates weighted using W2 longitudinal weights. ⱡ ¼ suppressed
estimate; AOR ¼ adjusted odds ratio; ENDS ¼ electronic nicotine delivery systems; P12 ¼ past 12; SE ¼ standard error.
aRestricted to those with W1 externalizing problem data.
bPercentages (%) represent the prevalence of Wave 1 lifetime externalizing problems.
cPercentages (%) and standard errors (SE) represent the prevalence of new tobacco use between W1 and W2 by W1 lifetime externalizing problems.
dAdjusted odds ratios (AOR) and 95% CI indicate the odds of new tobacco use between W1 and W2 as a function of lifetime externalizing problems;
adjusted for age group (12–17 vs 18–24 years), gender, race, ethnicity, ever any substance use at W1, and internalizing problems at W1.
eIncludes snus pouches, smokeless tobacco excluding snus pouches, and dissolvables.
fModel did not run.
gEstimate has been suppressed because it is statistically unreliable. It is based on a (denominator) sample size of less than 50, or the coefficient of
variation of the estimate (or its complement) is larger than 30%. Estimates for bidis, kreteks, and dissolvable tobacco have been suppressed based on
these criteria.
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TABLE S3 New Tobacco Product Use at Wave 2 by Lifetime Severity of Combined Internalizing and Externalizing Problems at
Wave 1 Among 9,067 Youth (Aged 1217 Years) and 1,466 Young Adult (Aged 1824 Years) Never Tobacco Users in the
Population Assessment of Tobacco and Health (PATH) Study (continued below)
New Tobacco Use
Between Waves
1 and 2 (Never-P12
Month Use)
New Tobacco
Use Among W1
Never Usersa
Wave 1 Mental Health Problems
No/Low/Moderate Internalizing/
No/Low/Moderate
Externalizing Severity
(Referent) 52.8%b
High Internalizing
Severity
7.9%b
Unweighted
n
Weighted
% (SE)
Unweighted
n
Weighted
% (SE)c
Unweighted
n
Weighted
% (SE)c AORd 95% CId
Any tobacco 1285 13.3 (.5) 460 10.3 (.6) 110 15.6 (1.9) 1.6 (1.1, 2.1)
Cigarettes 384 4.1 (.2) 126 3.1 (.3) 44 7.4 (1.3) 2.4 (1.5, 3.9)
ENDS 1120 10.4 (.4) 386 7.6 (.5) 86 10.7 (1.4) 1.4 (1.0, 1.9)
Any cigar 294 3.4 (.3) 98 2.4 (.3) 30 5.7 (1.1) 2.5 (1.6, 4.0)
Traditional cigars 131 1.8 (.2) 50 1.5 (.2) ⱡe ⱡe ⱡe ⱡe
Cigarillos 214 2.3 (.2) 74 1.6 (.2) 21 4.3 (1.0) 3.0 (1.8, 5.0)
Filtered cigars 55 0.5 (.1) 18 0.4 (.1) ⱡe ⱡe ⱡe ⱡe
Hookah 391 4.7 (.3) 149 3.9 (.4) 36 6.3 (1.1) 1.5 (0.9, 2.5)
Any smokeless tobaccof 117 1.1 (.1) 54 1.1 (.2) ⱡe ⱡe ⱡe ⱡe
Smokeless tobacco
(excluding snus
pouches)
90 0.9 (.1) 46 1.0 (.2) ⱡe ⱡe ⱡe ⱡe
Snus pouches 39 0.4 (.1) 14 0.3 (.1) ⱡe ⱡe #g
Note: Population of interest: Wave 1 youth (aged 1217 years, n ¼ 8,873) and young adults (aged 1824 years, n ¼ 1,455) who never used any tobacco
at Wave 1; estimates weighted using W2 longitudinal weights. Estimates for pipe, bidis, kreteks, and dissolvable tobacco have been suppressed based
on these criteria. Statistically significant associations at p < 0.05 indicated in boldface type. ⱡ ¼ suppressed estimate; AOR ¼ adjusted odds ratio;
P12 ¼ past 12; SE ¼ standard error.
aRestricted to those with Wave (W) 1 internalizing problem and externalizing problem data.
bPercentages (%) represent the prevalence of Wave 1 lifetime mental health problems.
cPercentages (%) and standard errors (SE) represent the prevalence of new tobacco use between W1 and W2 by W1 lifetime mental health problems.
dAdjusted odds ratios (AOR) and 95% CI indicate the odds of new tobacco use between W1 and W2 as a function of lifetime mental health problems;
adjusted for age group (1217 vs 1824 years), gender, race, ethnicity, and ever any substance use at W1.
eEstimate has been suppressed because it is statistically unreliable. It is based on a (denominator) sample size of less than 50, or the coefficient of
variation of the estimate (or its complement) is larger than 30%.
fIncludes snus pouches, smokeless tobacco excluding snus pouches, and dissolvables.
gModel did not run.
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Wave 1 Mental Health Problems
High
Externalizing
Severity
18.6%b
High Internalizing/
High Externalizing
Severity
20.6%b
Unweighted
n Weighted % (SE)c AORd 95% CId
Unweighted
n
Weighted
% (SE)c AORd 95% CId
282 14.3 (1.2) 1.3 (1.1, 1.7) 433 19.5 (1.1) 1.9 (1.6, 2.3)
74 3.2 (.5) 1.0 (0.7, 1.4) 140 6.2 (.6) 2.0 (1.5, 2.6)
252 11.7 (1.0) 1.4 (1.1, 1.8) 396 16.2 (1.0) 1.9 (1.6, 2.4)
65 3.2 (.5) 1.1 (0.7, 1.7) 101 5.3 (.6) 2.1 (1.5, 3.0)
22 1.3 (.3) 0.7 (0.3, 1.3) 46 2.8 (.5) 1.8 (1.1, 3.0)
51 2.3 (.4) 1.3 (0.8, 2.0) 68 3.2 (.4) 1.8 (1.3, 2.7)
7 0.3 (.1) 0.5 (0.2, 1.3) 25 1.1 (.3) 2.3 (1.0, 5.1)
70 4.4 (.7) 1.1 (0.7, 1.7) 136 6.5 (.6) 1.7 (1.3, 2.3)
26 1.1 (.3) 0.8 (0.5, 1.4) 30 1.2 (.2) 1.0 (0.6, 1.7)
17 0.8 (.2) 0.6 (0.3, 1.1) 22 0.8 (.2) 0.8 (0.5, 1.4)
ⱡ
e
ⱡ
e #g 12 0.6 (.2) #g
TABLE S3 New Tobacco Product Use at Wave 2 by Lifetime Severity of Combined Internalizing and Externalizing Problems at
Wave 1 Among 9,067 Youth (Aged 1217 Years) and 1,466 Young Adult (Aged 1824 Years) Never Tobacco Users in the
Population Assessment of Tobacco and Health (PATH) Study (continued)
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